Both in Biotechnology
Editas Medicine vs REGENXBIO
Over the past year EDIT returned −12.7% and RGNX returned −40.0%; their daily moves had a correlation of 0.46.
EDIT −12.7% RGNX −40.0%Growth of $1, one year, split-adjusted
| Metric | EDIT | RGNX |
|---|---|---|
| Price | $2.67 | $7.20 |
| Market cap | $410.1M | $475.3M |
| Today | −8.87% | −2.83% |
| 1 month | +6.0% | −3.0% |
| 6 months | −7.9% | −21.1% |
| Year to date | +30.2% | −50.0% |
| 1 year | −12.2% | −43.9% |
| Revenue growth (YoY) | +232.3% | +405.7% |
| Gross margin | 100.0% | 99.0% |
| Net margin | −153.3% | 21.0% |
| P/E (TTM) | — | — |
| Price / sales | 8.7× | 2.7× |
| Net cash | $155.9M | $105.5M |
| Dividend yield | — | — |
| Volatility (60d) | 81.4% | 86.5% |
| Short % of float | 25.7% | 19.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).